Skip to main content
Equibles
NUVB logo

NUVB · Nuvation Bio Inc. · Webcasts, Transcripts & Audio

Track NUVB — free

Use NUVB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NUVB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.57 -0.01 (-0.11%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.60B
Shares
351.12M
Volume · Oct 26 1.31M Avg daily vol (3M) 5.41M

Nuvation Bio Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Nuvation Bio Inc. (NUVB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-09
Nuvation Bio Inc. (NUVB) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Confident tone Ibtrozi (Deptrosi) commercial launch and revenue growth Durability and chronic-disease launch dynamic ROS1 testing rates and education
Revenue
$31.69M
▲ 555.6% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Nuvation Bio Inc. (NUVB) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-20
Nuvation Bio Inc. (NUVB) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Nuvation Bio Inc. (NUVB) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
Nuvation Bio Inc. (NUVB) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Confident tone Iptrozy commercial launch and patient dynamics Future guidance and reporting Clinical data, durability and safety profile
Revenue
$83.23M
▲ 2598.7% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
Confident tone IBTROZI Commercial Launch Pipeline Termination (NUV-1511) ROS1 / TRKb Mechanism
Revenue
$41.87M*
▲ 633.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript
Confident tone IBTROZI U.S. Commercial Launch Efficacy and Durability Data Pipeline and Partnerships
Revenue
$13.12M
▲ 1704.7% YoY
Diluted EPS
$-0.16
Gross margin
74.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nuvation Bio Inc. (NUVB) Q2 2025 Earnings Call Transcript
Confident tone Efficacy and safety profile Pipeline and safusitinib (FAFU) Regulatory discussions
Revenue
$4.83M
▲ 236.8% YoY
Diluted EPS
$-0.17
Gross margin
46.7%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-06-12
Nuvation Bio Inc. (NUVB) June 12, 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-07
Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript
Confident tone Taletrectinib PDUFA and approval Competitive positioning vs. repotrectinib/crizotinib Safusidenib pipeline asset
Revenue
$3.08M
Diluted EPS
$-0.16
Gross margin
32.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–13 of 13 webcasts
Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 30 filings 30 filers Visit website Investor relations